UK Asks For Views On Safe Regulation Of New Cancer Therapies

2025-02-03 03:08:15

(MENAFN- Kuwait News Agency (KUNA)) LONDON, Feb 3 (KUNA) -- The Medicines and Healthcare products Regulatory Agency (MHRA) has today launched a consultation on regulatory guidance for individualised mRNA cancer immunotherapies (colloquially referred to as cancer vaccines).
The eight-week consultation was launched Monday and will run until March 31, 2025. The MHRA is asking all stakeholders, including developers of these medicines, to provide comments, after which the guidance will be updated. The UK regulator also welcomes comments from members of the public, including people affected by cancer.
The guidance aims to streamline pathways for bringing these therapies through to patients, without compromising on robust safety principles, noted a government statement. (end)
nbs

MENAFN03022025000071011013ID1109163061

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.